コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 are lacking on the cardiovascular safety of degludec.
2 ra, 0.2 for liraglutide, and 2.6 for insulin degludec.
3 /liraglutide (n = 278; maximum dose, 50 U of degludec/1.8 mg of liraglutide) or glargine (n = 279; no
4 th type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819
5 xploratory phase 2 study showed that insulin degludec, a basal insulin with an action profile of long
6 pants, 472 were randomly assigned to insulin degludec and 157 to insulin glargine; all were analysed
7 (99%) of 755 participants randomly allocated degludec and 248 (99%) of 251 allocated glargine were in
8 05 episodes per patient-year of exposure for degludec and glargine) but were too low for assessment o
9 9% points (0.07), respectively, with insulin degludec and insulin glargine (estimated treatment diffe
10 mol/L or severe) were similar in the insulin degludec and insulin glargine groups (42.54 vs 40.18 epi
12 compared the efficacy and safety of insulin degludec and insulin glargine, both administered once da
13 nation of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogu
15 ra, by 1.4% (1.0) to 6.9% (1.1) with insulin degludec, and by 1.3% (1.1) to 7.0% (1.2) with liragluti
16 ditions used in current formulations whereas degludec behaved as a dihexamer with evidence of further
17 med to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with
18 doses of the synthetic insulins glargine and degludec currently used in patient therapy are character
20 sis by sedimentation equilibrium showed that degludec exhibited reversible interaction between mono-
21 randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or
22 randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or
23 rgine group (estimated treatment difference [degludec-glargine] 0.08%, 95% CI -0.05 to 0.21), confirm
24 ter 1 year, HbA(1c) decreased by 1.1% in the degludec group and 1.2% in the glargine group (estimated
25 cemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group,
26 tcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (
27 (nausea 8.8 vs 19.7%), although the insulin degludec group had the fewest participants with gastroin
28 glucose level was significantly lower in the degludec group than in the glargine group (128+/-56 vs.
29 person-years' exposure (PYE) in the insulin degludec group vs 2462.7 episodes per 100 PYE in the ins
30 ycemia were 277.1 per 100 PYE in the insulin degludec group vs 428.6 episodes per 100 PYE in the insu
31 Lira group, eight (2%) of 412 in the insulin degludec group, and 14 (3%) of 412 in the liraglutide gr
34 To test whether treatment with basal insulin degludec is associated with a lower rate of hypoglycemia
37 astrointestinal adverse events reported with degludec/liraglutide (adverse events, 79 for degludec/li
39 aking glargine and metformin, treatment with degludec/liraglutide compared with up-titration of glarg
41 udec/liraglutide vs glargine (-1.81% for the degludec/liraglutide group vs -1.13% for the glargine gr
42 with weight gain with glargine (-1.4 kg for degludec/liraglutide vs 1.8 kg for glargine; ETD, -3.20
44 es (episodes/patient-year exposure, 2.23 for degludec/liraglutide vs 5.05 for glargine; estimated rat
49 ve insulin glargine U100 followed by insulin degludec (n = 252) and randomized 1:1 to morning or even
50 ve insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or even
51 o to receive once-daily subcutaneous insulin degludec or glargine, stratified by previous insulin reg
52 ated blocked allocation sequence, to insulin degludec or insulin glargine without stratification by u
55 of hypoglycemia among patients who received degludec than among those who received basal insulin gla
56 isodes requiring assistance) were lower with degludec than glargine (11.1 vs 13.6 episodes per patien
57 lower proportion of patients in the insulin degludec than in the insulin glargine U100 group experie
58 l confirmed hypoglycaemia was 25% lower with degludec than with glargine (4.41 vs 5.86 episodes per p
59 The primary outcome was non-inferiority of degludec to glargine measured by change in HbA(1c) from
60 The primary outcome was non-inferiority of degludec to glargine, assessed as a reduction in HbA(1c)
62 od were 1.6% (95% CI, 0.6%-2.7%) for insulin degludec vs 2.4% (95% CI, 1.1%-3.7%) for insulin glargin
63 isk factor, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced
64 poglycemia, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced
65 overall symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were 185.6 vs 265.4 ep
66 turnal symptomatic hypoglycemia with insulin degludec vs insulin glargine U100 were 55.2 vs 93.6 epis
67 cturnal symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were also seen for the
68 etes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the
70 nwarranted with newer basal insulins such as degludec, which are associated with lower risks of hypog
71 s the non-inferiority of IDegLira to insulin degludec (with an upper 95% CI margin of 0.3%), and the
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。